Drug insight: Bleeding after percutaneous coronary intervention - Risks, measures and impact of anticoagulant treatment options

Nature Clinical Practice Cardiovascular Medicine

Volumn 2, Issue 9, 2005, Pages 465-474

  Rothman, Martin T ^a  

^a LONDON CHEST HOSPITAL   (United Kingdom)

Author keywords

Anticoagulation; Direct thrombin inhibitors; Glycoprotein IIb IIIa inhibitors; Heparin; PCI

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ARGATROBAN; CLOPIDOGREL; DESULFATOHIRUDIN; ENOXAPARIN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; FONDAPARINUX; HEPARIN; HIRULOG; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; THROMBIN INHIBITOR; TICLOPIDINE; TIROFIBAN;

AGE; ANEMIA; ANTICOAGULATION; BLEEDING; BLOOD TRANSFUSION; CLINICAL PRACTICE; CLINICAL PROTOCOL; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DEATH; DISEASE SEVERITY; DRUG BINDING; DRUG EFFICACY; DRUG EXCRETION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; HEMATOMA; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; LENGTH OF STAY; META ANALYSIS; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT OUTCOME;

AGE FACTORS; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTICOAGULANTS; ANTITHROMBINS; HEMORRHAGE; HOSPITAL COSTS; HUMANS; PLATELET AGGREGATION INHIBITORS; RISK FACTORS; TREATMENT OUTCOME;

EID: 24044434637     PISSN: 17434297     EISSN: None     Source Type: Journal    
DOI: 10.1038/ncpcardio0311     Document Type: Review

References (61)

1. Weitz JI and Bates SM (2000) Beyond heparin and aspirin: new treatments for unstable angina and non-Q-wave myocardial infarction. Arch Intern Med 160: 749-758
2. Silber S et al. (2005) Guidelines for percutaneous coronary interventions. Eur Heart J 26: 804-847
3. Patrono C et al. (2004) Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European society of cardiology. Eur Heart J 25: 166-181
4. Topol EJ et al. (1993) Use of a direct antithrombin, hirulog, in place of heparin during coronary angioplasty. Circulation 87: 1622-1629
5. Lopez LM (2003) Clinical challenges of bleeding in percutaneous coronary intervention. Am J Health-Syst Pharm 60 (Suppl 3): S8-S14
6. Kinnaird TD et al. (2003) Incidence, predictors, and prognostic implications of bleeding and blood transfusion following percutaneous coronary interventions. Am J Cardiol 92: 930-935
7. Lauer MA et al. (2002) Practice patterns and outcomes of percutaneous coronary interventions in the United States: 1995 to 1997. Am J Cardiol 89: 924-929
8. Rao AK et al. (1988) Thrombolysis in Myocardial Infarction (TIMI) Trial - phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol 11: 1-11
9. Berkowitz SD et al. (1997) Incidence and predictors of bleeding after contemporary thrombolytic therapy for myocardial infarction. The Global Utilization of Streptokinase and Tissue plasminogen activator for Occluded coronary arteries (GUSTO) I Investigators. Circulation 95: 2508-2516
10. Maroo A and Lincoff AM (2004) Bivalirudin in PCI: an overview of the REPLACE-2 trial. Semin Thromb Hemost 30: 329-336
11. Berkowitz SD et al. (2001) Prospective comparison of hemorrhagic complications after treatment with enoxaparin versus unfractionated heparin for unstable angina pectoris or non-ST-segment elevation acute myocardial infarction. Am J Cardiol 88: 1230-1234
12. Goodman SG et al. (2003) Randomized evaluation of the safety and efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. Circulation 107: 238-244
13. Stone GW et al. (2004) Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial: study design and rationale. Am Heart J 148: 764-775
14. Moscucci M (2002) Frequency and costs of ischemic and bleeding complications after percutaneous coronary interventions: rationale for new antithrombotic agents. J Invasive Cardiol 14 (Suppl B): 55B-64B
15. Montalescot G et al. (2005) Description of modern practices of percutaneous coronary intervention and identification of risk factors for adverse outcome in the French nationwide OPEN registry. Heart 91: 89-90
16. Lincoff AM et al. (2003) Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 289: 853-863
17. Moscucci M et al. (2003) Predictors of major bleeding in acute coronary syndromes: the global registry of acute coronary events (GRACE) Eur Heart J 24: 1815-1823
18. Nikolsky E et al. (2004) Vascular complications associated with arteriotomy closure devices in patients undergoing percutaneous coronary procedures: a meta-analysis. J Am Coll Cardiol 44: 1200-1209
19. Koreny M et al. (2004) Arterial puncture closing devices compared with standard manual compression after cardiac catheterization. Systematic review and metaanalysis. JAMA 291: 350-357
20. Saghir T et al. (2003) Transradial diagnostic and percutaneous coronary intervention. J Coll Physicians Surg Pak 13: 242-247
21. Louvard Y et al. (2004) Comparison of transradial and transfemoral approaches for coronary angiography and angioplasty in octogenarians (the OCTOPLUS study). Am J Cardiol 94: 1177-1180
22. Agostoni P et al. (2004) Radial versus femoral approach for percutaneous coronary diagnostic and interventional procedures: systematic overview and meta-analysis of randomized trials. J Am Coll Cardiol 44: 349-356
23. Kassam S et al. (2004) Radial versus femoral access for rescue percutaneous coronary intervention with adjuvant glycoprotein IIb/IIIa inhibitor use. Can J Cardiol 20: 1439-1442
24. Mann T et al. (1998) Stenting in acute coronary syndromes: a comparison of radial versus femoral access sites. J Am Coll Cardiol 32: 572-576
25. Smith SC Jr et al. (2001) ACC/AHA guidelines for percutaneous coronary intervention (Revision of the 1993 PTCA guidelines): a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1993 Guidelines for Percutaneous Transluminal Coronary Angioplasty). J Am Coll Cardiol 37: 2239i-2239ixvi
26. Chew DP et al. (2005) Bivalirudin versus heparin and glycoprotein IIb/IIIa inhibition among patients with renal impairment undergoing percutaneous coronary intervention (a subanalysis of the REPLACE-2 trial). Am J Cardiol 95: 581-585
27. Rao SV et al. (2004) Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. JAMA 292: 1555-1562
28. Milkovich G and Gibson G (2003) Economic impact of bleeding complications and the role of antithrombotic therapies in percutaneous coronary intervention. Am J Health Syst Pharm 60 (Suppl 3): S15-S21
29. Cohen DJ et al. (2004) Economic evaluation of bivalirudin with provisional glycoprotein IIB/IIIA inhibition versus heparin with routine glycoprotein IIB/IIIA inhibition for percutaneous coronary intervention: results from the REPLACE-2 trial. J Am Coll Cardiol 44: 1792-1800
30. Becker DL et al. (1999) Exosites 1 and 2 are essential for protection of fibrin-bound thrombin from heparin-catalyzed inhibition by antithrombin and heparin cofactor II. J Biol Chem 274: 6226-6233
31. Bates SM and Weitz JI (2000) The mechanism of action of thrombin inhibitors. J Invasive Cardiol 12 (Suppl F): 27F-32F
32. Popma JJ et al. (2004) Antithrombotic therapy during percutaneous coronary intervention: the seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 (Suppl 3): 576S-599S
33. Popma JJ et al. (2001) Antithrombotic therapy in patients undergoing percutaneous coronary intervention. Chest 119: 321S-336S
34. Tolleson TR et al. (2003) Relationship between heparin anticoagulation and clinical outcomes in coronary stent intervention. J Am Coll Cardiol 41: 386-393
35. Chew DP et al. (2001) Defining the optimal activated clotting time during percutaneous coronary intervention. Circulation 103: 361-966
36. Hirsh J (1991) Heparin. N Engl J Med 324: 1565-1574
37. Klein W et al. (2003) Patterns of use of heparins in ACS. Correlates and hospital outcomes: the Global Registry of Acute Coronary Events (GRACE). Thromb Haemost 90: 519-527
38. Ferguson JJ et al. (2004) Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA 292: 45-54
39. Borentain M et al. (2005) Low-molecular-weight heparin vs unfractionated heparin in percutaneous coronary intervention: a combined analysis. Catheter Cardiovasc Interv 65: 212-221
40. Mehta SR et al. (2005) Arixtra® study in percutaneous coronary intervention: a randomised evaluation (ASPIRE) pilot trial. Circulation 111: 1390-1397
41. Warkentin TE et al. (1995) Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 332: 1330-1335
42. Campbell KR et al. (2000) Bivalirudin in patients with heparin-induced thrombocytopenia undergoing percutaneous coronary intervention. J Invasive Cardiol 12 (Suppl F): 14F-9
43. Singer RL et al. (1993) Complications from heparin-induced thrombocytopenia in patients undergoing cardiopulmonary bypass. Chest 104: 1436-1440
44. British Cardiovascular Intervention Society (2003) British Cardiovascular Intervention Society audit [http://www.bcis.org.uk/resources/audit/audit2003] (accessed 10 May 05)
45. de Queiroz Fernandes Araújo JO et al. (2004) Efficacy and safety of abciximab on acute myocardial infarction treated with percutaneous coronary interventions: a meta-analysis of randomized, controlled trials. Am Heart J 148: 937-943
46. Brener SJ et al. (1998) Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators. Circulation 98: 734-741
47. De Luca G et al. (2005) Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. JAMA 293: 1759-1765
48. Boeynaems JM et al. (2005) P2Y receptor antagonists in thrombosis. Curr Opin Investig Drugs 6: 275-282
49. Herbert JM et al. (2003) P2Y12, a new platelet ADP receptor, target of clopidogrel. Semin Vasc Med 3: 113-122
50. van Giezen JJ et al. (2005) Preclinical and clinical studies with selective reversible direct P2Y12 antagonists. Semin Thromb Hemost 31: 195-204
51. Nemergut C and Cheng JWM (2000) Use of direct thrombin inhibitors in acute coronary syndrome. Clin Ther 22: 937-948
52. European Medicines Agency (2005) [http://www.emea.eu.int/index/indexh1.htm] (accessed 10 May 05)
53. Hirahara T et al. (2004) Prospective randomized study of argatroban versus heparin anticoagulation therapy after percutaneous coronary intervention for acute myocardial infarction. J Cardiol 44: 47-52
54. Bittl JA et al. (2001) Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: final report reanalysis of the Bivalirudin Angioplasty Study. Am Heart J 142: 952-959
55. Kong DF et al. (1999) Clinical outcomes of bivalirudin for ischemic heart disease. Circulation 100: 2049-2053
56. Lincoff AM et al. (2004) Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial. JAMA 292: 696-703
57. Randomized Trial to Evaluate the Relative PROTECTion against Post-PCI Microvascular Dysfunction and Post-PCI Ischemia among Anti-Platelet and Anti-Thrombotic Agents. [http://www.timi.org/home.htm] (accessed 22 July 2005)
58. Collet JP et al. (2005) Non-ST-segment elevation acute coronary syndrome in patients with renal dysfunction: benefit of low-molecular-weight heparin alone or with glycoprotein IIb/IIIa inhibitors on outcomes. The Global Registry of Acute Coronary Events Eur Heart J [doi:10.1093/eurheartj/ehi337]
59. Hulot JS et al. (2005) Dosing strategy in patients with renal failure receiving enoxaparin for the treatment of non-ST-segment elevation acute coronary syndrome. Clin Pharmacol Ther 77: 542-552
60. Berger PB et al. 2005. The relation of renal function to ischemic and bleeding outcomes with 2 different glycoprotein IIb/IIIa inhibitors: the do Tirofiban and ReoPro Give Similar Efficacy Outcome (TARGET) trial. Am Heart J 149: 869-75
61. Chew DP et al. (2003) Bivalirudin provides increasing benefit with decreasing renal function: a metaanalysis of randomized trials. Am J Cardiol 92: 919-923